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A randomized prospective clinical trial compared com-
bined treatment with intraaortic balloon pumping and 
intravenous nitroglycerin for 4 to 5 days with routine 
clinical management in 20 patients with extensive myo-
cardium at risk for infarction as evidenced by a thallium 
defect score of 7.0 units or greater. No significant dif-
ferences in mortality or clinical outcome were observed 
between the 10 patients receiving the combined treat-
ment and the 10 receiving routine management. In 14 
patients two-dimensional echocardiograms obtained 6 to 
24 hours after the onset of symptoms and at follow-up 
6 to 16 days later (after completion of combined in-
traaortic balloon pumping plus nitroglycerin therapy) 
were analyzed to determine whether infarct segment or 
noninfarct segment lengths were affected by therapy. 
Among these 14 patients,S (3 receiving the combined 
therapy and 2 receiving routine management) demon-
strated an increase in infarct segment length of greater 
than 1.0 cm. Mean infarct segment length increased 0.30 
± 0.44 cm in patients receiving the combined therapy 
and 0.29 ± 0.36 cm in patients on routine management 
(p = NS). In contrast, noninfarct segment length in-
Several clinical trials (1-4) have reported beneficial effects 
of early administration of intravenous nitroglycerin in pa-
tients with acute myocardial infarction. In our own recently 
From the Department of Medicine, Division of Cardiology, The Johns 
Hopkins University School of Medicine, Baltimore, Maryland. This study 
was supported by a Specialized Center for Research in Ischemic Heart 
Disease Grant P50HL 17655 from the National Institutes of Health, Be-
thesda, Maryland. Dr. Flaherty was supported by National Heart, Lung, 
and Blood Institute Research Career Development Award K04-HLOOOI9 
from the National Institutes of Health. This paper was presented in part 
at the 56th Annual Scientific Sessions of the American Heart Association, 
Anaheim, California, November 1983. Manuscript received November 6, 
1984; revised manuscript received March 6, 1985, accepted March 29, 
1985. 
Address for reprints: John T. Flaherty, MD, The Johns Hopkins Hos-
pital, 600 North Wolfe Street, Baltimore, Maryland 21205. 
creased greater than 1.0 cm (mean increase 1.20 ± 0.39) 
in five of seven patients on routine management but in 
none of 7 patients receiving intraaortic balloon pumping 
plus nitroglycerin therapy (mean decrease 0.22 ± 0.20 
cm) (p < 0.05). No significant differences were noted in 
left ventricular ejection fraction, as measured by gated 
blood pool scintigraphy, or thallium perfusion defect 
score in a comparison of day 1 (pretreatment) with day 
4 thallium or day 7 to 14 gated blood pool scintigrams. 
Thus, in patients with extensive myocardium at risk, 
it is unlikely that a reduction in mortality or a significant 
improvement in myocardial perfusion or ventricular 
function can be obtained by early intervention with in-
traaortic balloon pumping in combination with nitro-
glycerin. Although this combined therapy failed to pre-
vent infarct segment lengthening (infarct expansion), the 
combined afterload-Iowering effects of intraaortic bal-
loon pumping and nitroglycerin did appear to prevent 
dilation or remodeling of noninfarcted segments during 
the first 2 weeks after acute myocardial infarction. 
(J Am Coli CardioI1985;6:434-46) 
published (5) clinical trial of intravenous nitroglycerin in 
patients with acute myocardial infarction, we demonstrated 
improvement in clinical outcomes and in scintigraphic in-
dexes of infarct size when 1) treatment was initiated within 
10 hours of symptom onset, and 2) the extent of myocardium 
at risk was small to moderate as evidenced by a thallium-
201 perfusion defect score between 1.0 and 7.0 units. How-
ever, no significant improvement in infarct size and, more 
important, no reduction in mortality were observed in pa-
tients with extensive myocardium at risk, as defined by a 
perfusion defect score of 7.0 units or greater. 
The present study was designed to test the hypothesis 
that the addition of intraaortic balloon counterpulsation ther-
apy to an intravenous infusion of nitroglycerin could provide 
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additive benefit, owing to the increased coronary perfusion 
pressure as well as the further reductions in both afterload 
and preload. Between 1980 and 1982, 206 patients under-
went intraaortic balloon catheter insertion at our institution. 
Among 105 patients in whom the percutaneous route of 
insertion was employed, balloon pump-related mortality was 
less than 1 % and irreversible limb damage occurred in fewer 
than 2% (6). In the absence of peripheral vascular disease, 
major vascular complications (the majority being reversible 
with vascular repair or embolectomy, or both) were en-
countered in only 6% of men and 19% of women utilizing 
the percutaneous method of insertion. In view of the high 
short-term mortality predicted by an admission thallium score 
of 7.0 units or greater, the risks associated with using an 
intraaortic balloon pump were judged to be acceptable. 
Methods 
Experimental Protocol 
Patient selection. Candidates for admission to this study 
included all patients admitted to the coronary care unit with 
a history of chest pain and electrocardiographic changes 
diagnostic or highly suggestive of acute myocardial infarc-
tion and with onset of symptoms within 12 hours of coronary 
care unit admission. Electrocardiographic changes consist-
ing of ST segment elevations or new ST segment depressions 
of 2 mm or greater were required and the admission thallium 
perfusion defect score had to be 7.0 units or greater (see 
following). The patients had to be in Killip class I or II at 
the time of study entry but could have been in Killip class 
III before initial therapy. Patients were excluded from study 
entry if they had absent or severely decreased femoral pUlses 
that would preclude balloon insertion if the patient had been 
so randomized. Other exclusion criteria included: 1) age 
greater than 70 years, 2) life-threatening diseases including 
recent cerebrovascular accident, new malignancy or severe 
renal disease defined by a blood urea nitrogen level greater 
than 100 mg/dl, 3) cardiogenic shock with blood pressure 
less than 90/60 mm Hg and evidence of peripheral organ 
hypoperfusion, and 4) clear clinical indications for intraaor-
tic balloon therapy, such as acute mitral regurgitation or 
ventricular septal rupture. Twenty patients met these entry 
criteria. 
Routine management. Oxygen, morphine and lido-
caine were administered according to standard clinical prac-
tice with lidocaine infusion started at 20 JLg/kg per min. All 
20 patients received full heparinization. In patients random-
ized to balloon pumping, administration of heparin was 
begun as soon as possible after balloon catheter insertion; 
for patients randomized to standard therapy, heparin was 
initiated by constant infusion to maintain the partial throm-
boplastin time at 2.0 to 2.5 times control values. An initial 
12 lead electrocardiogram and an initial creatine kinase blood 
sample were obtained immediately after coronary care unit 
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admission. A thallium-201 perfusion scintigram was ob-
tained as soon as possible and only if the computer-assisted 
thallium defect score was 7.0 units or greater was the patient 
eligible for randomization (see following). A technetium-
99m-labeled red blood cell gated blood pool scan was then 
obtained, the patient was examined by one of the senior 
investigators and a final determination made as to the pa-
tient's eligibility for randomization. A 24 hour Holter am-
bulatory electrocardiographic recording was begun and a 
two-dimensional echocardiogram and a 48 lead precordial 
surface potential map were obtained. Total creatine kinase 
(CK) blood levels with quantitative MB isoenzyme deter-
minations were obtained every 4 hours for 48 hours, every 
8 hours for 72 hours and every 12 hours for the remainder 
of hospital stay. Daily 12 lead electrocardiograms were ob-
tained while the patient was in the coronary care unit. 
Patients were randomized without prior consent using the 
Zelen randomization technique (7). For the 10 patients ran-
domized to intraaortic balloon pumping plus intravenous 
nitroglycerin treatment, informed consent was requested and 
received before initiation of therapy. For the 10 patients 
randomized to routine management, informed consent was 
not obtained until the time of follow-up scintigraphic stud-
ies. The protocol was approved by our Joint Committee on 
Clinical Investigation on January 31, 1981. 
Treatment protocol. For patients randomized to the ex-
perimental treatment, intravenous infusion of nitroglycerin 
was begun and the infusion rate titrated stepwise until a 
10% lowering of mean arterial pressure was obtained but 
with an absolute lower limit for blood pressure of 90/60 
mm Hg. The 48 lead precordial electrocardiogram map was 
repeated 1 hour after the final intravenous nitroglycerin 
maintenance infusion rate was achieved. Intraaortic balloon 
pump therapy was initiated by percutaneous catheter inser-
tion and an SMEC 1300 control console as soon as possible 
after initiation of nitroglycerin therapy; this was followed 
by full heparinization and the drawing of blood for a control 
platelet count. Blood pressures recorded during intraaortic 
balloon pumping were: systolic = patient's peak systolic 
pressure (during balloon deflation) and diastolic = patient's 
peak diastolic pressure (during balloon inflation). The pre-
cordial map was repeated I hour after initiation of balloon 
pump therapy. Two-dimensional echocardiograms were ob-
tained on day 2 and at intervals of approximately every 
other day for the next 2 weeks. 
Informed consent for follow-up scintigraphic examina-
tions was obtained from patients randomized to routine man-
agement 4 days after coronary care unit admission. The 
thallium perfusion scintigram was repeated on day 4 in all 
patients. In the patients treated with the balloon pump, the 
scintigram was obtained while they were still receiving in-
traaortic balloon pump and nitroglycerin therapy. Although 
not part of the study protocol, cardiac catheterization could 
be performed during balloon pump therapy if the patient's 
attending physician judged it to be clinically indicated. Bal-
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loon pump therapy was then tapered over at least 24 hours 
and the balloon pump catheter was removed. On day 7 to 
14 after coronary care unit admission the gated blood pool 
scan was repeated, as were the two-dimensional echocar-
diogram, a 48 lead precordial map and a 24 hour Holter 
monitor recording. two months after coronary care unit 
admission, rest and exercise thallium perfusion scintigrams 
were obtained, as well as a gated blood pool scan at rest, 
a standard 12 lead electrocardiogram and a final 24 hour 
Holter monitor recording. 
Data Acquisition and Analysis 
Echocardiographic methods. A baseline two-dimen-
sional echocardiogram was obtained less than 24 hours after 
acute myocardial infarction. In the patients treated with com-
bined balloon pumping and nitroglycerin, the ultrasound 
study was obtained after initiation of therapy and then re-
peated at approximately 2 day intervals. For comparison 
with the baseline echocardiogram, the most technically ad-
equate echocardiogram obtained between 6 and 16 days after 
admission, when balloon pumping plus nitroglycerin ther-
apy had been completed, was chosen for analysis. The method 
of obtaining anterior and posterior segment lengths was 
similar to that used in a previously published study of acute 
infarct dilation (8). Minor axis cross-sectional echocardio-
graphic views were obtained at each study with a Varian 
V-3000 echocardiograph. The transducer was swept from 
the base toward the apex with special attention paid to the 
tips of the papillary muscles, which served as internal land-
marks. To permit return to the same echocardiographic win-
dow in serial examinations, a method of locating the trans-
ducer using bony landmarks was developed (8). A line from 
the jugular notch to the xiphoid process served as a refer-
ence. The transducer position was located by two measure-
ments: 1) the distance down the reference line from the 
jugular notch to the level of the transducer, and 2) the 
distance along the line perpendicular to the reference from 
the reference line to the transducer. The degree of lateral 
rotation and elevation of the upper body was noted at the 
time of the first study and maintained at subsequent studies. 
The two papillary muscles and the transducer position 
on the chest wall defined a minor axis plane through the 
ventricle which could be located from study to study. Mea-
surements of ventricular dimensions were obtained from 
minor axis views at the level of the papillary muscle tips. 
A Varian light-pen system was used to perform mea-
surements on end-diastolic (at the onset of the QRS com-
plex) video frames. Reference lines were drawn through the 
papillary muscles perpendicular to the endocardium. The 
anterior endocardial segment length was defined as the dis-
tance along the anterior endocardium between the centers 
of the papillary muscles. The posterior endocardial segment 
length was similarly defined for the posterior wail. The mean 
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value of at least three measurements of each segment was 
recorded. 
All measurements were made by a single observer who 
viewed studies from each patient in random order without 
knowledge of the sequence of studies. In the previous study, 
intraobserver variability in six studies was 0.23 ± 0.18 cm 
(mean ± SD) and variability between two observers in six 
studies was 0.37 ± 0.40 cm. 
Control measurements. To determine the limits of nor-
mal anterior and posterior segment lengths, the mean and 
standard deviation of these dimensions were calculated for 
13 normal control subjects (7). The mean (± SD) anterior 
endocardial length was 8.6 ± 1.2 cm and the mean posterior 
endocardial length was 5.3 ± 1.0 cm. From these data an 
upper limit of normal was defined as the mean + 2 SD. 
Thus, the upper limit of normal was 11.0 cm for the anterior 
and 7.3 cm for the posterior endocardial arc length. 
Scintigraphic studies. Thallium-20l and gated blood 
pool scintigrams were acquired with a gamma camera 
(Technicare 420 or 120) fitted with a medium sensititivity 
or general all purpose low energy parallel-hole collimator, 
and interfaced to a dedicated computer (Medical Data Sys-
tems). For the thallium studies, 1.5 to 2.0 mCi thallous-
201 chloride was injected intravenously and 400 K count 
images were acquired 10 minutes later in anterior and 40 
and 60° left anterior oblique views in a 128 x 128 matrix 
format on a magnetic disc. Thallium-201 results in radiation 
exposure of 0.24 rad/mCi to the total body, 0.39 rad/mCi 
to the kidney, 0.30 rad/mG to the testes and 0.17 mCi to 
the heart, exposures that are within Food and Drug Admin-
istration guidelines. Immediately after the thallium study 
was completed, a gated cardiac blood pool scintigram was 
acquired in anterior and approximately 40° left anterior oblique 
views (to best define the interventricular septum) without 
caudal angulation in 32 x 32 format, interpolated to 64 x 
64, with a 2 x software zoom and utilizing 20 mCi of 
technetium-99m as in vivo labeled erythrocytes. The radia-
tion exposure for technetium-99m is 0.009 rad/mCi to the 
whole body, 0.052 rad/mCi to the heart and 0.016 rad/mCi 
to the liver and gonads, exposures that are again within 
Food and Drug Administration guidelines. A cardiac shield 
was used to improve image quality for both thallium and 
blood pool studies. 
Initial and posttreatment thallium perfusion scintigrams 
were analyzed by the "circumferential profiles" computer-
assisted technique (9). A defect score was obtained for each 
study, reflecting both the extent and intensity of perfusion 
deficit. A curve of normalized thallium activity versus an-
gular location was generated and superimposed on empir-
ically determined normal limits with alignment of the apex. 
The defect score was calculated by integrating the area of 
the patient's curve below normal, equivalent to the total 
reduction in activity divided by the total number of radii, 
or average reduction per radius. This method of computer 
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scoring has been shown to have acceptably high intraob-
server and interobserver reproducibility (9), 
Gated cardiac blood pool scintigrams were analyzed with 
a commercial computer program (MUGE). Regions of in-
terest were generated semiautomatically over the left ven-
tricle for each frame in the cardiac cycle with a combined 
second derivative and count threshold algorithm. A back-
ground region was generated automatically lateral and in-
ferior to the left ventricle in the end-systolic frame, five 
pixels wide and two pixels removed from the computer-
generated left ventricular edge. From these regions of in-
terest, a background-corrected left ventricular time-activity 
curve was obtained and left ventricular ejection fraction was 
calculated as (end-diastolic counts - end-systolic counts)/end-
diastolic counts. The lower limit of normal for ejection 
fraction in our laboratory is 50%. Regional wall motion was 
assessed visually in two views in each of eight left ventric-
ular segments by two observers who were unaware of patient 
identity and therapy. Segments were judged to be normal, 
hypokinetic, akinetic or dyskinetic, and the total number of 
akinetic and dyskinetic segments was determined. 
Twenty-four hour Holter monitor electrocardio-
graphic recordings. The Holter monitor recordings were 
read blindly by a trained technician using an electroscanner 
(Avionics Model 660) at a scanning speed 60 times normal. 
Arrhythmias were printed at a paper speed of 25 mmls and 
analyzed without knowledge of patient assignment. Ven-
tricular arrhythmias were classified according to the mod-
ified criteria of Lown: class 0, no premature ventricular 
complexes; class I, uniform premature ventricular com-
plexes (less than 30/h); class 2, uniform premature ventric-
ular complexes (30/h or more) during at least I hour of 
monitoring; class 3, multiform premature ventricular com-
plexes; class 4, premature ventricular complexes in couplets 
or greater (including ventricular tachycardia). Evaluation of 
the Holter monitor recordings included the total premature 
ventricular complex count as well as the maximal Lown 
classification noted during the 24 hours. 
Creatine kinase blood levels. Total serum creatine ki-
nase (CK) blood levels were measured by a modified Rosalki 
technique (10) and CK-MB isoenzyme blood levels were 
measured using the Coming creatine kinase isoenzyme method 
(agarose gel electrophoresis with ftuorometric quantitation). 
Upper limits of normal for total CK were 50 IU/liter for 
men and 40 IU/liter for women. 
Precordial mapping studies. Patients with electrocar-
diographic changes in anterior or lateral leads, or both, 
underwent serial 48 lead precordial QRS and ST segment 
mapping, Details of the methods have been described pre-
viously (II). Recordings were made at 20 mm = I mV 
calibration, and ST segment voltages were measured 80 ms 
after the termination of the QRS complex. All records were 
read without knowledge of therapy, and any patients de-
veloping an intraventricular cbnduction defect (QRS dura-
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tion > lOOms) were excluded. Preservation of R wave volt-
age, expressed as percent of control, was analyzed in 
contiguous leads showing ST elevation of I mm or greater 
on the initial map (12). 
Statistical analysis. All results are expressed as mean ± 
1 SD. Two-tailed unpaired Student's t tests and analysis of 
variance were employed for continuous variables. Chi-square 
and Fisher's exact tests were employed for nonparametric 
comparisons. Ninety-five percent confidence limits of the 
differences in the means were computed for ejection fraction 
and thallium perfusion defect scores. 
Assuming a 6 month mortality in the routine management 
group of 90%, a sample size of 15 patients in each treatment 
group was calculated to have an 80% probability of iden-
tifying a reduction in mortality from 90 to 50% at the 
p < 0.05 level. A stratified randomization scheme was 
utilized to allocate subjects into the two treatment groups. 
Variables chosen from stratification included: I) age greater 
or less than 60 years, 2) location of the acute infarction 
(anterior versus inferior), 3) prior myocardial infarction, and 
4) cardiomegaly, as defined by a cardiothoracic ratio of 
greater than 0.55 on the admission anteroposterior chest X-
ray study. Because of the potential interaction of these vari-
ables with possible outcomes or responses to therapy, it was 
judged necessary to allocate patients into the two treatment 
groups so that the proportional distribution of each of these 
variables was as nearly equal as possible. The stratified 
allocation of patients into the two treatment groups was 
maintained by our data management coordinator (C. K.) who 
was blinded to all outcome data. Preliminary examination 
of the exact proportion of each of the control variables in 
each treatment group was made after 10 patients had been 
randomized and no adjustment for allocation was necessary 
for the four stratification variables. 
Results 
Clinical characteristics of the study group. Clinical 
characteristics of the 10 patients randomized to receive in-
traaortic balloon counterpulsation plus nitroglycerin therapy 
and the 10 patients randomized to receive routine medical 
management are presented in Table I. There were no sig-
nificant differences in mean age, sex, cardiomegaly, history 
of prior infarction, history of prior congestive heart failure, 
history of angina of greater than 1 month's duration, infarct 
location or Killip class. 
Management of other medications before and during 
the study period. Eleven patients had received sublingual 
nitroglycerin before initiation of the study, 5 in the balloon 
pump group and 6 in the routine management group. Sev-
enteen had received morphine, 10 in the balloon pump group 
and 7 in the routine management group, with a mean dose 
of 18 mg. Five had received furosemide, two in the treat-
ment and three in the routine management group. Three 
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Table 1. Clinical Characteristics of Study Group 
Age (yr) 
Sex (male) 
Cardiomegaly (CTR >0.55) 
History of prior infarction 
History of prior heart failure 
History of angina 
(> I mo duration) 
Infarct location 
Anterior 
Inferior 
Killip class 
I 
II 
III 
IABP + TNG 
Therapy 
(n = 10) 
52 ± II 
9 
4 
4 
0 
7 
7 
3 
3 
7 
0 
Routine Medical 
Management 
(n = 10) 
53 ± II 
8 
4 
4 
I 
4 
9 
2 
7 
CTR = cardiothoracic ratio on admission anteroposterior chest X-ray 
study; (ABP + TNG = intraaortic balloon pumping plus intravenous 
nitroglycerin; n = number of patients. 
patients received nitroprusside ihfusion transiently before 
study entry, two in the balioon pump group and one in the 
routine management group. After initiation of the study, all 
patients received lidocaine and heparin according to pro-
tocol. Additional morphine was required by five of the pa-
tients receiving balloon pump therapy and four of the pa-
tients on routine management. Atropine was required in one 
patient in the balloon pump group. Furosemide was admin-
istered to six patients in each of the two treatment groups. 
By protocol none of the patients given balloon pump therapy 
received nitroprusside during the study period; however, 
four of the patients on routine management received nitro-
prusside with a mean dose of 65 ± 58 JLg/min. Additional 
sublingual nitroglycerin was administered for treatment of 
ischemic chest pain to two of the patients receiving balloon 
pump therapy and three of the patients on routine management. 
Details of nitroglycerin and intraaortic balloon pump 
therapy. The mean interval between the onset of chest pain 
and initiation of the thallium-20 I myocardial perfusion scan 
in the 10 patients subsequently randomized to nitroglycerin 
and intraaortic balloon pump therapy was 5.0 ± 2.6 hours; 
in 7 of the 10 scanning was performed within 6 hours of 
the onset of symptoms. The same interval in the 10 patients 
randomized to receive routine management was 5.7 ± 3.4 
hours, and in 8 patients scanning was performed less than 
6 hours after symptom onset. The mean interval to complete 
the scintigraphic evaiuation and initiate nitroglycerin infu-
sion was 3.6 ± 1.6 hours, and the mean duration of titration 
was 2.1 ± 1.5 hours. The mean final infusion rate employed 
was 32 ± 23 JLg/min, and the mean duration of intravenous 
therapy was 5.6 ± 3.6 days. Thus, 5 of the 10 patients had 
I1itroglycerin therapy initiated within 7 hours of the onset 
of acute infarction and 7 of 10 within 10 hours; the mean 
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time interval to treatment for the entire group was 8.7 ± 
2.8 hours. This interval was nearly 1 liz hours shorter than 
that in our previous nitroglycerin study (5). 
The mean interval between the onset of nitroglycerin 
therapy and the initiation of intraaortic balloon pumping 
was 1.9 ± 1.1 hours. therefore a mean of 10.2 ± 2.9 
hours elapsed between the onset of symptoms and the ini-
tiation of intraaortic counterpulsation therapy. Seven of nine 
patients had balloon pump therapy initiated within 10.5 
hours of the onset of symptoms; one patient who could not 
have an intraaortic balloon pump catheter inserted because 
of severe aortoiliac atherosclerotic disease received only 
nitroglycerin therapy. Inti'aabrtic balloon counterpulsation 
at I: I augmentation was performed for a mean of 4.6 ± 
1.9 days. Tapering was begun by decreasing the ratio of 
balloon inflation to cardiac cycles, preceded by a stepwise 
decrease of the balloon volume in 500/0 of the patients. The 
mean duration of tapering was 34 ± 25 hours. 
Hemodynamic responses. Institution of nitroglycerin 
therapy resulted in a mean decrease in systolic pressure of 
12 mm Hg (9%), a mean decrease in diastolic pressure of 
13 mm Hg (13%) and a decrease in heart rate of 6 beats/min 
(6%) (Fig. I, Table 2). The addition of intraaortic ballooh 
Figure 1. Hemodynamic response to intraaortic balloon pumping 
(lABP) and intravenous nitroglycerin (TNG) therapy. Measure-
ments were made immediately before (PRE) and 1 hour after 
(POST) initiation of intraaortic balloon pumping and nitroglycerin 
therapy, respectively (mean ± SD). 
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Table 2. Hemodynamic Responses in the Treatment Group 
Hemodynamic Responses to Nitroglycerin Therapy (n = to) 
Systolic pressure 
(mm Hg) 
Diastolic pressure 
(mmHg) 
Heart rate (min - ') 
Before Nitroglycerin 
137 ± 28 
98 ± 18 
98 ± 20 
After Nitroglycerin Mean Changes 
125 ± 29 -12 (9%) 
85 ± 14 - 13 (13%) 
92 ± 12 - 6 (6%) 
Hemodynamic Responses to Addition of IABP 
to Nitroglycerin Therapy (n = 9) 
Before IABP After IABP Mean Changes 
Diastolic pressure 82 ± 20 121 ± 27 +39 (49%) 
(mmHg) 
Systolic pressure 125 ± 33 t03 ± 24 -22(18%) 
(mmHg) 
Heart rate (min - ') 97 ± to 93 ± 15 - 4 (3%) 
Values are expressed as mean ± SO. IABP = intraaortic balloon pumping; n = number of patients. 
counterpulsation resulted in a further decrease in peak sys-
tolic arterial pressure of 22 mm Hg (18%) and, in contrast, 
an increase in diastolic pressure of 39 mm Hg (49%), cal-
culated by subtracting diastolic arterial pressure during ni-
troglycerin therapy from peak diastolic pressure during bal-
loon pumping. The combination of intraaortic balloon 
counterpulsation and intravenous nitroglycerin resulted in a 
decrease in systolic arterial pressure of 34 mm Hg (25%) 
and a decrease in heart rate of 5 beats/min (5%), both of 
which are important determinants of myocardial oxygen 
demand. A 23 mm Hg (23%) increase in aortic diastolic 
pressure was also observed and this increase in coronary 
perfusion pressure would act to augment myocardial oxygen 
supply. 
Clinical outcome (2 week follow-up). Clinical outcome 
during the first 14 days after coronary care unit admission 
is presented in Table 3. No significant differences in clinical 
outcome were observed between patients receiving com-
bined intraaortic balloon pump and nitroglycerin therapy 
and those receiving routine management. Four early cardiac 
deaths were noted in the combined treatment group and three 
in the routine management group. Myocardial infarct ex-
tension as documented by a secondary increase in total CK 
of greater than 100 IU/liter with greater than 8% myocardial-
specific CK isoenzymes was observed in one patient in the 
combined treatment group. Severe left ventricular failure, 
as evidenced by Killip class IV status on day 10, was ob-
served in three patients in this group. Postinfarction angina 
developed 3.2 ± 4.4 days after admission in six patients 
receiving combined treatment, and 2.8 ± 2.9 days after 
admission in four patients in the routine management group. 
Cardiac catheterization data. Six of the 10 patients in 
the balloon pump plus nitroglycerin treatment group under-
went cardiac catheterization; 3 of these patients were still 
on the intraaortic balloon pump. Clinical indications for 
catheterization varied, but in general were based on hemo-
dynamic stability and the possibility of salvage of reversibly 
ischemic myocardium in the face of the high short-term 
mortality predicted by a thallium defect score of 7,0 units 
or greater. Unfortunately, all six of these patients demon-
strated triple vessel coronary disease with severe distal ves-
sel involvement; as a result, none was a candidate for op-
eration and therefore none underwent bypass surgery during 
the ensuing 12 months of follow-up, None of the 10 patients 
in the routine management group underwent cardiac cath-
eterization or bypass surgery during 12 months of follow-
up study. The failure to catheterize any of the patients in 
the routine management group reflected clinical practice at 
that time for patients with an extensive acute myocardial 
infarction. 
Table 3. Clinical Outcomes at Days \0 to 14 After 
Myocardial Infarction 
Cardiac death before day 14 
Infarct extension 
Killip class on day to 
I 
II 
III 
IV 
Postinfarct angina 
Holter Lown class 4 PVCs 
Catheterization 
IABP + TNG 
Therapy 
(n = 10) 
4 
4 
0 
3 
6 
3 
6 
Routine 
Management 
(n = 10) 
3 
0 
5 
3 
0 
0 
4 
I 
0 
IABP + TNG = intraaortic balloon pumping plus nitroglycerin; n = 
number of patients; PVCs = premature ventricular complexes. 
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Table 4. Clinical Outcomes at 2 Months After 
Myocardial Infarction 
IABP + TNG Routine 
Therapy Management 
(n = 10) (n = 10) 
Cardiac death 5 3 
Heart failure class (NYHA) 
Class I 3 3 
Class II 3 
Unknown 
Angina class (NYHA) 
Class I 3 4 
Class II 0 
Class III I 0 
Class IV 0 
Holter Lown class 4 I 
Recurrent MI 0 0 
IABP + TNG = intraaortic balloon pumping plus nitroglycerin; MI 
= myocardial infarction; n = number of patients; NYHA = New York 
Heart Association. 
Clinical outcomes (2 month foUow-up). During the first 
2 months of follow-up study there were five cardiac deaths 
and one noncardiac death in the group receiving intraaortic 
balloon pumping plus nitroglycerin and three cardiac deaths 
in the group receiving routine management (Table 4). Be-
tween 2 and 12 months of follow-up study one additional 
cardiac death occurred in a patient receiving routine man-
agement. Heart failure, anginal status and incidence of Lown 
class 4 arrhythmias after 2 months of follow-up study were 
comparable in both treatment groups (Table 4). There was 
no recurrent myocardial infarction noted in either group 
during this 2 month period of observation. 
A 
16 
lACC Vol. 6, No.2 
August 1985:434-46 
Two-dimensional echocardiographic assessment of in-
farct and noninfarct segment lengths (Fig. 2). Comparison 
of two-dimensional echocardiograms performed on day 1 
with echocardiograms performed 6 to 16 days later revealed 
a mean increase in infarct segment length measured in a 
cross-sectional view of the left ventricle at the level of the 
papillary muscles of 0.3 ± 0.4 cm in seven patients re-
ceiving intraaortic balloon pump plus nitroglycerin therapy 
and 0.3 ± 0.4 cm in seven patients on routine management 
(p = NS) (Fig. 2). Infarct segment lengths measured within 
the first 24 hours after admission exceeded 11.0 cm in six 
patients (Fig. 2A, left asterisks). Our previous study had 
defined an upper limit of normal for the anterior segment 
of 11.0 cm (8). Thus, infarct segment length showed evi-
dence of early (pretreatment) infarct expansion in four pa-
tients receiving balloon pump therapy and two on routine 
management. Importantly, none of these six patients had a 
history of a prior myocardial infarction, which could have 
provided an alternative explanation for "early expansion." 
Three additional patients demonstrated late infarct expan-
sion as evidenced by an increase in infarct segment length 
of greater than 1 cm during the 6 to 16 day period of 
observation: one patient receiving balloon pump therapy and 
two on routine management (Fig. 2A, right asterisks). In 
addition, two patients receiving balloon pump therapy who 
had demonstrated early pretreatment expansion demon-
strated further lengthening of greater than 1 cm in the infarct 
segment. Thus, it would appear that the experimental treat-
ment had no effect on infarct segment length, which trans-
lates to no effect on early infarct expansion. 
In contrast, a significant differential response was noted 
in the response of the length of the noninfarcted segment 
B 
Figure 2. Effects of combined intraaortic 
balloon pumping (IABP) and intravenous 
nitroglycerin (TNG) therapy on infarct 
segment length (panel A) and noninfarct 
segment length (panel B) compared with 
routine management. Measurements were 
made on cross-sectional views of the left 
ventricle from two-dimensional echocar-
diograms obtained early (day 1) and late 
(days 6 to 16). Asterisks indicate infarct 
segment expansion on the left of panel A 
by an absolute criterion (> 11.0 cm) and 
on the right of panel A by a criterion of 
1.0 cm or greater increase in infarct seg-
ment length. Asterisks on the right of 
panel B indicate an increase in non infarct 
segment length of 1.0 cm or greater. In-
dividual patient responses in all survivors 
and mean ± SD are presented. The mean 
changes in the noninfarcted segment 
lengths in the two treatment groups were 
significantly different at the p < 0.05 level. 
In contrast, the mean changes in the in-
farct segment lengths were not signifi-
cantly different (p = NS). 
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DAY 1 
to nitroglycerin and balloon pump therapy (Fig. 2B). Pa-
tients receiving this therapy had a small 0.2 ± 0.2 em (3%) 
reduction in the noninfarcted segment length, whereas pa-
tients on routine management had a significant 1.2 ± 0.4 
em (19%) lengthening of the non infarcted segment (p < 
0.05). Five of the seven patients receiving routine manage-
ment demonstrated an increase in the non infarcted segment 
length of 1 em or greater (Fig. 2B, right asterisks). In 
contrast, none of the seven patients receiving intraaortic 
balloon plus nitroglycerin therapy had an increase in non-
infarcted segment length greater than 0.4 cm. 
A similar beneficial effect was noted on the overall en-
docardial circumferential measurement. The mean total cir-
cumference did not change (17.3 ± 0.8 versus 17.4 ± 1.0 
em) in patients receiving nitroglycerin and intraaortic bal-
loon pump therapy, but in contrast increased from 15.6 ± 
1.8 to 18.5 ± 1.2 em in patients on routine management 
(p = NS). Five of seven patients receiving routine man-
agement had an increase in total endocardial circumference 
of greater than 1.0 em; whereas only two of seven patients 
receiving nitroglycerin and intraaortic balloon therapy showed 
such an increase, and both were patients who had early 
pretreatment plus late (posttreatment) expansion of the in-
farct segment. Thus, it appears that early therapy with ni-
troglycerin plus intraaortic counterpulsation, which offers a 
combination of afterload-lowering effects, is able to prevent 
stretching of noninfarcted myocardial segments, thereby 
minimizing remodeling of the left ventricle, which has been 
described as a late complication of acute myocardial infarction. 
Assessment ofteft ventricular function (Fig. 3A, Table 
5). Comparison of the left ventricular ejection fraction mea-
sured on day I before initiation of therapy and a measure-
ment made on day 7 to 14 in eight surviving patients in 
each treatment group revealed no significant difference be-
tween those receiving balloon pump therapy and those on 
routine management, with a small mean increase of 1.4% 
in the treatment group (34.1 ± 5.3% [SEM] on day 1 versus 
35.5 ± 6.0% on day 10) and a small mean decrease of 
2.6% in the routine management group (37.6 ± 3.9% on 
day 1 versus 35.0 ± 4.4% on day 10) (p = NS). Only two 
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Figure 3. Effects of combined intraaortic bal-
loon pumping (lABP) and intravenous nitro-
glycerin (TNG) therapy on ejection fraction 
measured by gated blood pool scintigraphy (panel 
A) and thallium-20 1 perfusion defect score (panel 
B) compared with routine management. Ejection 
fraction and defect score were measured before 
initiation of treatment (day I) and then again 7 
to 14 days later, after both therapies had been 
discontinued (day 10). Individual patient re-
sponses in all survivors and mean ± SD are 
presented. The mean changes in ejection fraction 
and perfusion defect score in the two treatment 
groups were not significantly different (p = NS). 
patients demonstrated a 10% or greater improvement in 
ejection fraction. Although both of these patients were in 
the intraaortic balloon plus nitroglycerin treatment group, 
one was the patient who could not have the balloon catheter 
inserted because of severe peripheral vascular disease. Ex-
cluding this latter patient, the mean ejection fraction for the 
nine patients receiving the combination of intravenous ni-
troglycerin and intraaortic balloon pumping was only 34.4 
± 6.8%, which would represent only 0.4% improvement 
in ejection fraction. With OUr total sample size of 20 pa-
tients, we estimated a confidence level on the 4.0% differ-
ence in ejection fraction responses observed between the 
two treatment groups. Computation of the 95% confidence 
limits for the difference in mean responses between treat-
ment groups revealed that the maximal improvement in ejec-
tion fraction that could have been missed with this sample 
size was 10.9%. Likewise, there was no difference noted 
between treatment groups in the number of akinetic or dys-
kinetic segments comparing day 1 with day 7 to 14 gated 
blood pool scans. 
Thallium·201 perfusion defect scores (Fig. 3B, Table 
6). Comparison of the thallium perfusion defect score ob-
tained before therapy on day 1 and the defect score on day 
Table 5. Left Ventricular Function Data 
Day I (pretreatment) 
Day 7 to 14 
2 mo 
Day I (pretreatment) 
Day 7 to 14 
2 rna 
Ejection Fraction (%) 
IABP + TNG Therapy Routine Management 
(n = 8) (n = 8) 
34 ± 15 38 ± II 
36 ± 17 35 ± 12 
38 ± 13 (4 pts) 36 ± 13 (7 pts) 
Number of Akinetic or Dyskinetic Segments 
IABP + TNG Therapy 
(n = 7) 
3.5 ± 1.5 
3.5 ± 1.8 
1.8 ± 1.5 (4 pts) 
Routine Management 
(n = 7) 
4.2 ± 1.6 
3.1 ± 1.7 
2.4 ± 1.5 (7 pts) 
pts = patients; other abbreviations as in Table I. 
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Table 6. Thallium Myocardial Perfusion Data 
Days I to 4 
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IAPB + TNG Therapy 
(n = 7) 
Routine Management 
(n = 8) 
Thallium defect score 
(day I [pretreatment]) (U) 
Thallium defect score 
(day 4) (U) 
Number of abnonnal segments 
(day I [pretreatment]) 
Number of abnormal segments 
(day 4) 
14.7 ± 4.4 12.5 ± 7.7 
10.6 ± 3.2 7.5 ± 4.2 
7.9 ± 2.8 6.8 ± 2.1 
7.4 ± 3.0 5.6 ± I.7 
2 Months After Myocardial Infarction 
IABP + TNG Therapy 
(n = 4) 
Routine Management 
(n = 7) 
Number of abnormal segments 
During exercise 
At rest 
Thallium defect score 
during exercise (U) 
Maximal heart rate 
attained (beats/min) 
Exercise duration (min) 
Abbreviations as in Table I. 
4 (obtained during balloon pumping in the patients receiving 
combination therapy) revealed a mean decrease in thallium 
defect score of only 4.1 ± 1.6 units (SEM) (28%) in seven 
treated patients, compared with a decrease of 5,0 ± 1.8 
units (39%) in eight patients receiving routine medical man-
agement (p = NS). Computation of the 95% confidence 
limits revealed that the maximal improvement in thallium 
defect score with nitroglycerin and balloon pump therapy 
versus routine management that could have been missed 
with this sample size was 15%. Semiquantitative analysis 
of the number of abnormally perfused myocardial segments 
(15 total segments per study) revealed no significant dif-
ferences between treatment groups. Comparison of thallium 
2000 
Figure 4. Effects of combined intraaortic balloon :J 1600 pumping (IABP) and intravenous nitroglycerin (TNG) "-
therapy on the peak. blood level of the MB isoen- ::J H 
zyme of creatine kinase (CK-MB) (panel A) and 1200 
on the rate of rise of CK-MB (panel B) compared (D ~ 
with routine management (mean ± SD). The peak I 
blood level and the rate of rise of CK-MB in the ~ BOO U 
two treatment groups were not significantly differ- ~ 
ent (p = NS). « w 
Q. 400 
0 
A 
4.5 ± 2.4 
3.8 ± I.7 
8.0 ± 7.2 
146 ± 26 
8.1 ± 2.3 
5.8 ± 2.6 
3.7 ± 3.1 
12.1 ± 7.9 
138 ± 40 
8.0 ± 2.9 
defect scores and numbers of abnormal segments at rest and 
during exercise 2 months later also failed to reveal any 
significant differences. 
Holter electrocardiographic data. Lown class 4 pre-
mature ventricular complexes were observed in seven pa-
tients receiving treatment and six on routine management 
on the day I Holter monitor recording. Class 4 premature 
ventricular complexes were observed on the day 10 Holter 
monitor recording in three patients receiving treatment com-
pared with one patient on routine management. Class 3 
premature ventricular complexes were found in ohe patient 
in each group. The remaining patients demonstrated pre-
mature ventricular complexes in class 0 or I. 
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Creatine kinase blood levels (Fig. 4). Mean peak blood 
levels of the creatine kinase-MB isoenzyme reached 1,352 
IU/liter in the patients receiving treatment compared with 
587 IUlliter in the patients receiving routine medical man-
agement (p = NS) (Fig. 4A). Likewise, the mean rate of 
increase in the balloon pump patients was 64.6 IU/liter per 
h compared with 41.8 IU/liter per h in the patients receiving 
routine management, calculated by dividing the peak CK-
MB blood level by the time interval between the onset of 
chest pain and the peak blood level (p = NS) (Fig. 4B). 
In one patient peak CK-MB blood levels increased abruptly 
to greater than 6,000 IU/liter after balloon pump insertion, 
with the total CK blood level peaking at 40,000 IU/liter. 
These cardiac enzyme findings would be compatible with 
increased washout of CK enzym~ associated with improved 
perfusion of infarcted myocardium. 
Precordial mapping studies. Analysis of ST segment 
changes in six patients in each treatment group confirmed 
the acute antiischemic effects of both nitroglycerin and 
intraaortic balloon pumping. The sum of ST changes 
(l ST) decreased 47% during the first hour of intravenous 
nitroglycerin therapy compared with a 16% decrease during 
a comparable time period in patients receiving routine man-
agement (p < 0.05). Likewise, l ST decreased an additional 
36% during the I hour after institution of intraaortic balloon 
pumping compared with a 29% decrease during the same 
time period in the patients receiving routine management 
(p = NS). 
However, analysis of R wave voltages in those leads 
with initial ST elevations revealed no evidence of improved 
preservation between the two treatment groups. The sum of 
R wave changes (l R) decreased 20% from 21 ± 7 mm 
on day I to 15 ± 4 mm on day 7 to 14 in six patients 
treated with balloon pumping plus nitroglycerin therapy, 
but decreased only 6% from 18 ± 5 to 17 ± 6 mm in six 
patients receiving routine management (p = NS). 
Adverse reactions. Transient hypotension was noted in 
6 of 10 patients during intravenous nitroglycerin therapy. 
In 3 patients the hypotension was of a minor degree requiring 
no change in the infusion rate, in 2 the infusion rate was 
readjusted downward and in only I was discontinuation of 
the infusion required. Two patients had mild headache or 
nausea, which responded to a small reduction of the infusion 
rate. Two patients encountered vascular complications with 
balloon pump therapy, developing arterial insufficiency which 
required catheter embolectomy at the time of elective bal-
loon catheter removal. One patient developed a mild infec-
tion at the site of balloon catheter insertion which cleared 
rapidly with antibiotic therapy. One patient sustained a sig-
nificant hemorrhage after self-removal of a percutaneously 
inserted balloon catheter, most likely secondary to mental 
confusion associated with a low cardiac output state. This 
patient subsequently died in cardiogenic shock 25 days after 
admission. 
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Discussion 
Infarct expansion. Infarct expansion, as first described 
by Hutchins and Bulkley (13), describes the process of 
thinning and dilation of the infarcted myocardial wall. In 
experimental animals this process is observed to occur with 
large transmural infarctions as early as 6 to 24 hours after 
the onset of acute infarction and to progress with time (14). 
Clinical as well as experimental studies (15) have suggested 
that the extent of infarction relative both to the area of 
endocardium involved and to the transmural extent of in-
farction is the major determinant of infarct expansion. 
Evidence of infarct expansion was already present in 6 
(55%) of II patients with a large anterior transmural myo-
cardial infarction on the first two-dimensional echocardio-
gram performed 6 to 24 hours after the onset of symptoms. 
Four of these six patients were already receiving "maximal" 
afterload-Iowering therapy at the time this initial measure-
ment was made, yet none had a history of prior myocardial 
infarction. Three patients, two with anterior and one with 
inferior transmural infarction, showed their first evidence 
of infarct expansion on the follow-up echocardiogram per-
formed 6 to 16 days later, when they were no longer re-
ceiving balloon pumping and intravenous nitroglycerin ther-
apy. Two of the six patients with evidence of pretreatment 
infarct expansion also showed evidence of further expan-
sion. Thus, we conclude that intraaortic counterpulsation 
therapy failed to prevent in-hospital lengthening of the in-
farct segment, because three of five patients showing evi-
dence of in-hospital infarct expansion had received the ex-
perimental treatment. This finding would also tend to refute 
the argument that the presence of the combined afterload-
lowering therapy at the time ofthe initial measurement might 
only have delayed and not prevented subsequent infarct 
segment lengthening, once the afterload-Iowering therapy 
was discontinued. 
Postinfarction ventricular remodeling. Recently La-
mas and Pf~ffer (16) described the effect of extent of trans-
mural infarction on subsequent measurements of left ven-
tricular end-diastolic volume. They suggested that left 
ventricular cavity dilation is the result of the remodeling of 
both infarcted and noninfarcted myocardium, which may 
contribute to deterioration of left ventricular function in the 
chronic phase of acute myocardial infarction. The results 
of the present study, also carried out in patients with ex-
tensive acute myocardial infarction, suggest that early (in-
hospital) remodeling of non infarcted segments of myocar-
dium can be prevented by initiation of afterload-Iowering 
therapy at the time of coronary care unit admission, a ther-
apeutic hypothesis that can be tested in future clinical stud-
ies. During the 6 to 16 day period of observation, five of 
the seven patients receiving routine management demon-
strated an increase greater than 1.0 cm in the endocardial 
segment length of non infarcted regions of myocardium. The 
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finding that two of these five patients did not show evidence 
of infarct expansion suggests that expansion was not a re-
quired stimulus for stretching of adjacent noninfarcted myo-
cardium. In contrast, none of the seven patients receiving 
the combined afterload-lowering therapy demonstrated an 
increase in non infarcted segment length of even 0.4 cm. In 
fact, four of these seven patients demonstrated an absolute 
decrease in noninfarcted segment length, even though five 
of the seven had shown early or late expansion, or both, of 
the infarct zone. 
It would appear from these findings that left ventricular 
remodeling is, at least in part, an early event occurring 
within the first 2 weeks of an extensive acute transmural 
myocardial infarction, long before significant collagen for-
mation, fibrosis or other later phase mechanisms of healing 
of infarcted tissue would be expected. The exact mechanism 
or mechanisms by which combined intraaortic balloon 
pumping and intravenous nitroglycerin therapy prevents re-
modeling of non infarcted myocardium remains unclear. We 
might speculate that once the Starling mechanism is invoked 
to compensate for the loss of a significant fraction of the 
left ventricular contractile mass, the stretching of sarco-
meres is to some extent irreversible. In contrast, if an after-
load-lowering therapy applied early can provide at least 
partial nemodynamic compensation until the compliance of 
the infarct decreases, then this potentially irreversible 
stretching of noninfarcted muscle might be avoided. 
Mechanisms of the antiischemic effects of intraaortic 
balloon pumping and nitroglycerin. Intraaortic balloon 
counterpulsation, by augmenting aortic diastolic pressure, 
is capable of increasing coronary perfusion and at the same 
time, by decreasing aortic systolic pressure (an index of 
afterload) and left ventricular end-diastolic pressure (an in-
dex of preload), is capable of decreasing myocardial oxygen 
demand. The combination of nitroglycerin, which also de-
creases afterload and preload (17-19) and in addition dilates 
coronary arteries (20), some coronary stenoses (20,21) and 
intercoronary collateral channels as well (22-25), could 
theoretically provide additive reduction in myocardial ox-
ygen demand plus additive improvement in oxygen supply 
to regions of ischemic myocardium. 
Previous studies of intraaortic balloon pump therapy 
and infarct size. Roberts et al. (26), using an open chest 
anesthetized model of canine myocardial infarction, dem-
onstrated significant reduction in myocardial infarct size 
when intraaortic balloon pumping was initiated 3 hours after 
acute coronary artery ligation. Also using a canine model, 
Swank et al. (27) noted increased collateral blood flow to 
regions of myocardium distal to an acute coronary artery 
ligation. They found that the improvement in collateral flow 
was primarily in the subepicardial layer, which is the layer 
that has greatest potential for salvage, according to a recent 
pathologic study in humans by Freifeld et al. (28). Sasayama 
et al. (29) used a canine model with implanted ultrasonic 
crystals to show that intraaortic balloon pumping improved 
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segmental contraction abnormalities in the reversibly isch-
emic border zone. Laas et al. (30) demonstrated the im-
portance of there being pre-existing intercoronary collateral 
channels for an increase in ischemic zone flow to be obtained 
with intraaortic balloon pumping. They failed to obtain a 
reduction in infarct size in a swine model in which these 
pre-existing channels were essentially absent. 
Prognostic significance of admission scintigraphic 
findings. In a previous retrospective study (31) we deter-
mined the prognostic significance of thallium-20l myo-
cardial perfusion defect scores obtained within 12 hours of 
the onset of chest pain in patients with acute myocardial 
infarction. Thirteen of 42 patients studied had defect scores 
of 7.0 units or greater, and of these 13 patients, 6 (42%) 
died during the hospital aqmission, 8 (62%) died within 6 
months and 12 (92%) died within 9 months. In the remaining 
29 patients with an admission defect score of less than 7.0 
units, none died during initial hospitalization and only 2 
(7%) died within the next 6 months. In a subsequent pro-
spective study (32),14 of91 patients with a thallium defect 
score of 7.0 or greater demonstrated a 6 month mortality 
rate of 64%. Mortality in the remaining 77 patients with a 
thallium score of less than 7.0 units was only 8%. The 
sample size for the present study was therefore chosen as-
suming a 1 year mortality of approximately 90% in a group 
of patients with a thallium perfusion defect score of 7.0 
units or greater. To have an 80% chance of identifying a 
reduction in mortality from 90 to 50% at the p less than 
0.05 level, a sample size of 15 patients in each treatment 
group would be required. 
Early in the course of the present study it became apparent 
that the short-term mortality rate in patients randomized to 
routine management was less than that observed in the pre-
vious studies. In fact, only 3 of the first 10 patients ran-
domized to receive routine management died during the first 
2 months of follow-up study. One possible explanation for 
the apparent reduction in control group mortality is that 
thallium scans were obtained much earlier relative to the 
onset of chest pain than in the two previous studies. Earlier 
thallium scans appear to show greater contrast between isch-
emic and nonischemic regions of myocardium, which would 
tend to increase the defect score for a given circumferential 
extent of decreased thallium perfusion. With a control group 
mortality rate of only 30%, the sample size needed to detect 
a decrease in mortality from 30 to 15% with intraaortic 
balloon pumping and intravenous nitroglycerin therapy would 
have required 90 to 100 patients in each treatment group, 
a number we considered prohibitive, especially with the 
early results showing five cardiac deaths in the balloon pump 
group during the same period of follow-up study. Therefore, 
we terminated the study after enrolling 20 patients and ana-
lyzed the data for other non mortality end points. 
Failure of intraaortic balloon pumping to reduce mor-
tality rate and scintigraphic indexes of infarct size. Our 
study showed no reduction in mortality in patients with 
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extensive myocardium at risk for infarction. Six of the seven 
early deaths occurred in patients with an admission ejection 
fraction of less than 22%. Four of these six patients had 
received balloon pumping plus nitroglycerin therapy and the 
remaining two had received routine management. Failure 
to improve scintigraphic indexes of "infarct size" in those 
patients with therapy initiated a mean of 10.2 hours after 
symptom onset might suggest either that the therapy initiated 
after most of the myocardium at risk had already undergone 
irreversible necrosis or that the anti-ischemic effects to be 
obtained from therapy were too weak to significantly alter 
the extent or severity of ischemia present. On the other hand, 
because coronary angiography performed in 6 of the 10 
patients receiving the experimental treatment did demon-
strate severe three vessel coronary disease, any potential for 
increasing intercoronary collateral blood flow by raising 
coronary perfusion pressure and dilating collateral channels 
may have been limited by the presence of flow-limiting 
stenoses in the adjacent coronary arteries supplying the col-
lateral vessels. 
Paired scintigraphic data were available only in those 
patients surviving long enough to have a second or follow-
up scan obtained. Improvement in scintigraphic indexes of 
infarct size, therefore, could be looked for only among short-
term survivors (that is, the "best" subgroup within the total 
group of patients randomized). Presumably, our exclusion 
from this analysis of patients who died before performance 
of a second scan (and were thus less likely to show im-
provement in scintigraphic indexes) only minimized the neg-
ative result. Calculation of the 95% confidence limits for 
the difference in mean responses (day I to day 10) for both 
scintigraphic end points indicated that it was unlikely that 
we missed a large beneficial effect even with our small 
sample size. 
Conclusions. The results of our study suggest that early 
application of intraaortic counterpulsation and intravenous 
nitroglycerin therapy in patients with extensive myocardium 
at risk for infarction I) failed to improve clinical outcome 
or reduce early cardiac death; 2) failed to improve myo-
cardial perfusion, as assessed by thallium scintigraphy; 3) 
failed to improve overall left ventricular function, as as-
sessed by gated blood pool scintigraphy; and 4) failed to 
prevent expansion of infarcted segments of myocardium. 
However, the combined afterload-lowering effects of in-
traaortic counterpulsation and nitroglycerin did appear to 
prevent expansion or remodeling of non infarcted segments 
of the left ventricular wall. Whether similar beneficial ef-
fects can be accomplished using noninvasive pharmacologic 
afterload-lowering therapy is unknown and could be the 
subject of future clinical studies. 
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